A randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T-Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Sponsor:
ECOG-ACRIN Cancer Research Group
Sponsor Study ID:
EA4232
CTO #:
104289
NCT Number:
NCT06724237
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
To demonstrate improvement in progression free survival (PFS) in the autologous stem cell transplant (ASCT) arm compared to the observation arm.
eConsent:
Not available
Study Documents:
Open Study Documents
(MUSC NetID required for document access)

For more information about this trial please contact the study team:

Trial opened at the following institutions:

Medical University of South Carolina